Filing Watching: Learn Why Phase4 Partners Ltd Just Purchased Albireo Pharma, Inc Stake?

Filing Watching: Learn Why Phase4 Partners Ltd Just Purchased Albireo Pharma, Inc Stake?

The New Phase4 Partners Ltd Holding in Albireo Pharma, Inc

Phase4 Partners Ltd filed with the SEC SC 13D form for Albireo Pharma, Inc. The form can be accessed here: 000119312516767879. As reported in Phase4 Partners Ltd’s form, the filler as of late owns 18.5% or 1,165,447 shares of the Health Care–company.

Albireo Pharma, Inc stake is a new one for the and it was filed because of activity on November 3, 2016. We feel this shows Phase4 Partners Ltd’s positive view for the stock.

Reasons Why Phase4 Partners Ltd Bought – Albireo Pharma, Inc Stock

Purpose of Transaction

The shares of Common Stock held by Phase4 GPLP, in its capacityas general partner of Phase4 III, were acquired as a result of the Transaction, when its ordinary shares of Albireo were exchanged for shares of Common Stock. The Reporting Persons intend to review their investment in the Issuer on a continuingbasis and, depending on various factors, including, without limitation, the Issuer’s financial position, the price of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Personsmay, in the future, take such actions with respect to their shares of the Issuer’s capital stock as they deem appropriate, including, without limitation: purchasing additional shares of Common Stock; selling shares of Common Stock; taking anyaction to change the composition of the Issuer’s board of directors; taking any other action with respect to the Issuer or any of its securities in any manner permitted by law or changing their intention with respect to any and all mattersreferred to in paragraphs (a)through (j)below in this Item4.

Except as otherwise described in this Schedule, none ofthe Reporting Persons currently has any plans or proposals that relate to or would result in: (a)the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b)an extraordinarycorporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c)a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d)any change in thepresent board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e)any material change in the present capitalization or dividendpolicy of the Issuer; (f)any other material change in the Issuer’s business or corporate structure; (g)any changes in the Issuer’s charter or bylaws or other actions which may impede the acquisition of control of the Issuer byany person; (h)causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association;(i)causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j)any action similar to any of thoseenumerated above.

Albireo Pharma, Inc Institutional Sentiment

Latest Security and Exchange filings show 34 investors own Albireo Pharma, Inc. The institutional ownership in Q3 2015 is low, at 60.66% of the outstanding shares. This is increased by 1418309 the total institutional shares. 38916338 were the shares owned by these institutional investors. In total 2 funds opened new Albireo Pharma, Inc stakes, 5 increased stakes. There were 10 that closed positions and 16 reduced them.

Rock Springs Capital Management Lp is an institutional investor bullish on Albireo Pharma, Inc, owning 4000000 shares as of Q3 2015 for 0.14% of its portfolio. Kevin Kotler Broadfin Capital Llc owns 5155530 shares or 0.13% of its portfolio. CA Longwood Capital Partners Llc have 0.65% of their stock portfolio for 2548830 shares. Further, Awm Investment Company Inc reported stake worth 0.38% of its US stock portfolio. The CT Great Point Partners Llc owns 3316966 shares. Albireo Pharma, Inc is 0.58% of the manager’s US portfolio.

Business Profile

Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Its clinical pipeline includes over two Phase II product candidates and one Phase III product candidate. Its pipeline includes A4250, A3384 and Elobixibat. The Company is developing A4250 as a treatment for pediatric orphan cholestatic liver diseases, such as progressive familial intrahepatic cholestasis (PFIC). The Company is developing A3384 for the treatment of bile acid malabsorption (BAM) disease. The Company is also developing Elobixibat as a treatment for chronic idiopathic constipation (CIC). A4250 and Elobixibat are selective inhibitors of the ileal bile acid transporter (IBAT). The Company has completed a Phase II clinical trial of a prototype of A3384 in over 19 subjects with BAM.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 0.64 in 2016 Q2. Its up 0.14, from 0.5 in 2016Q1. The ratio increased, as 6 funds sold all Albireo Pharma Inc shares owned while 5 reduced positions. 1 funds bought stakes while 6 increased positions. They now own 5.68 million shares or 19.38% less from 7.05 million shares in 2016Q1.

Group Inc One Trading Limited Partnership has invested 0% of its portfolio in Albireo Pharma Inc (NASDAQ:BIOD). Geode Mngmt Limited Co last reported 117,056 shares in the company. Acadian Asset Ltd Liability Corp last reported 0% of its portfolio in the stock. The New Jersey-based Kcg has invested 0% in Albireo Pharma Inc (NASDAQ:BIOD). Blackrock Institutional Trust Na, a California-based fund reported 25,914 shares. The North Carolina-based Bancorp Of America De has invested 0% in Albireo Pharma Inc (NASDAQ:BIOD). Ladenburg Thalmann Financial Services accumulated 0% or 1,000 shares. Plante Moran Financial Advisors Lc holds 1,470 shares or 0% of its portfolio. Goldman Sachs Gp holds 0% of its portfolio in Albireo Pharma Inc (NASDAQ:BIOD) for 17,021 shares. Susquehanna International Gru Llp holds 0% of its portfolio in Albireo Pharma Inc (NASDAQ:BIOD) for 11,166 shares. Deutsche Savings Bank Ag holds 772 shares or 0% of its portfolio. Blackrock Fund Advsr, a California-based fund reported 11,195 shares. Psagot Inv House Ltd holds 0% or 71,000 shares in its portfolio. Vanguard Group Inc holds 1.53M shares or 0% of its portfolio. Ameriprise, a Minnesota-based fund reported 12,300 shares.

Analysts await Albireo Pharma Inc (NASDAQ:BIOD) to report earnings on December, 15.

The stock closed at $19.46 during the last session. It is down 80.56% since April 4, 2016 and is uptrending. It has outperformed by 75.57% the S&P500.

Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The company has a market cap of $1.25 billion. The Firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. It currently has negative earnings. The Company’s clinical pipeline includes over two Phase II product candidates and one Phase III product candidate.

Albireo Pharma Inc (NASDAQ:BIOD) Ratings Coverage

Out of 2 analysts covering Biodel (NASDAQ:BIOD), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Biodel has been the topic of 2 analyst reports since December 18, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating given on Friday, December 18 by William Blair. The firm has “Neutral” rating by Ladenburg Thalmann given on Friday, December 18.

More notable recent Albireo Pharma Inc (NASDAQ:BIOD) news were published by: Quotes.Wsj.com which released: “News Albireo Pharma Inc.ALBO” on November 03, 2016, also Streetinsider.com with their article: “Form 3 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Sermon Charles” published on November 07, 2016, Streetinsider.com published: “Form 4 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Zorn Peter A” on November 07, 2016. More interesting news about Albireo Pharma Inc (NASDAQ:BIOD) were released by: Marketwired.com and their article: “Biodel Inc. and Albireo Limited Agree to Combine” published on May 25, 2016 as well as Globenewswire.com‘s news article titled: “Albireo Completes Transaction with Biodel to Create Publicly Traded Company …” with publication date: November 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment